Clinical trials: Demyelinating Diseases
Guillain-Barré Syndrome (GBS)
A Study of Imlifidase in Patients With Guillain-Barré Syndrome
The study participants are patients which have been diagnosed with Guillain-Barré Syndrome (GBS) and are planned to receive treatment with intravenous immunoglobulin (IVIg). IVIg is a standard of care treatment for GBS patients.
- Trial name
- NCT03943589
- Testing
- Imlifidase
- Where
- 11 sites in France, Netherlands and 1 more
- Volunteers
- 30 people
- Sponsor
- Hansa Biopharma AB
Multiple Sclerosis
Rebif® Pregnancy Registry
The objective for establishing the Rebif® Pregnancy Registry is to collect prospective outcomes data on women in the United States and Canada who have been exposed to Rebif® during their pregnancies.
- Trial name
- NCT00338741
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- EMD Serono
Multiple Sclerosis
A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis
This is a Phase II, randomized, double-blind, parallel group, placebo controlled, multicenter study to evaluate the safety and efficacy of Rituximab in adults with RRMS.
- Trial name
- NCT00097188
- Testing
- rituximab
- Where
- 31 sites in United States
- Volunteers
- 104 people
- Sponsor
- Genentech, Inc.
Multiple Sclerosis, Relapsing-Remitting
A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3, 6 and 12 months post treatment.
- Trial name
- NCT02587806
- Testing
- Autologous Bone Marrow-Derived Mononuclear Stem Cells, Liberation therapy
- Where
- 2 sites in India, Trinidad and Tobago
- Volunteers
- 69 people
- Sponsor
- Novo Cellular Medicine Institute LLP
Multiple Sclerosis
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial
The purpose of this study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months, or until it becomes commercially available whichever comes first, in subjects who…
- Trial name
- NCT00648908
- Testing
- Fampridine-SR
- Where
- 32 sites in United States, Canada
- Volunteers
- 269 people
- Sponsor
- Acorda Therapeutics
Relapsing Remitting Multiple Sclerosis
An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease
This is a multinational, multicenter, randomized, double-blind, parallel-group active extension of LAQ/5062 study (NCT00349193), assessing the tolerability, safety and efficacy of two doses (0.3 mg and 0.6 mg) of laquinimod…
- Trial name
- NCT00745615
- Testing
- Laquinimod
- Where
- 45 sites in Czechia, Germany and 7 more
- Volunteers
- 257 people
- Sponsor
- Teva Pharmaceutical Industries, Ltd.
Neuromyelitis Optica Spectrum Disorders
A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD)
The goal of this clinical trial is to evaluate the efficacy and safety, of JYP0061 in acute NMOSD patients. The main questions it aims to answer are: efficacy and safety of JYP0061 in acute NMOSD patients.
- Trial name
- NCT06697535
- Testing
- JYP0061, Intravenous Glucocorticoids, Oral Glucocorticoids
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Multiple Sclerosis
Digital Gait Analysis in the Home Environment of Patients With Multiple Sclerosis
The aim of this study is the development of novel telemedical examination methods based on sensor-based gait analysis in patients with multiple sclerosis (MS).
- Trial name
- MSgoesHome (NCT04771858)
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Medical Valley Digital Health Application Center GmbH
Multiple Sclerosis
Natalizumab High Titer Immunogenicity and Safety
The primary objective of the study was to evaluate the immunogenicity of natalizumab (Tysabri®) produced by a modified manufacturing process (natalizumab high titer; BG00002-E) administered intravenously (IV) to participants with…
- Trial name
- NCT00516893
- Testing
- BG00002-E (natalizumab high titer)
- Where
- 13 sites in United States
- Volunteers
- 113 people
- Sponsor
- Biogen
Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 in adult participants with neurological autoimmune diseases (AIDs), including Progressive…
- Conditions
- Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Autoimmune Encephalitis
- Trial name
- CRSP-AID-502 (NCT07804004)
- Testing
- CTX112
- Volunteers
- 220 people
- Sponsor
- CRISPR Therapeutics
Inherited Metabolic Diseases, Lysosomal Storage Disorders
ALD-101 Adjuvant Therapy of Unrelated Umbilical Cord Blood Transfusion (UCBT) in Patients With Inherited Metabolic Diseases
Eligible research subjects will receive an unrelated umbilical cord blood transfusion as a possible cure for their inherited metabolic disease.
- Conditions
- Inherited Metabolic Diseases, Lysosomal Storage Disorders, Peroxisomal Storage Diseases, Inborn Errors of Metabolism
- Trial name
- UCBT-002 (NCT00654433)
- Testing
- ALD-101
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Aldagen
Multiple Sclerosis
Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS) (CLARIFY MS)
The main purpose of the study was to assess the health-related quality of life (HRQoL) through the Multiple Sclerosis Quality of Life-54 Questionnaire (MSQoL-54) scale in highly-active relapsing multiple sclerosis (RMS)…
- Trial name
- NCT03369665
- Testing
- Mavenclad®
- Where
- 92 sites in Austria, Belgium and 16 more
- Volunteers
- 485 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Simvastatin as an Add-on Treatment to Interferon-beta-1a for the Treatment of Relapsing-Remitting Multiple Sclerosis
This study is to find out if there is any benefit to adding Simvastatin to Interferon-beta-1a in patients with Multiple Sclerosis.
- Trial name
- SIMCOMBIN (NCT00492765)
- Testing
- Interferon-beta-1a, Simvastatin
- Where
- Denmark
- Volunteers
- 380 people
- Sponsor
- Biogen
Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
This study will evaluate the pharmacokinetics, pharmacodynamics, safety, immunogenicity, and radiological and clinical effects of subcutaneous (SC) administration of ocrelizumab compared with the intravenous (IV) infusion of…
- Trial name
- Ocarina II (NCT05232825)
- Testing
- Ocrelizumab IV, Ocrelizumab SC, Methylprednisolone IV
- Where
- 37 sites in United States, Brazil and 6 more
- Volunteers
- 236 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis
Effect of MD1003 in Spinal Progressive Multiple Sclerosis
The purpose of this study is to demonstrate the superiority of MD1003 over placebo in the disability of patients suffering from progressive multiple sclerosis and especially those with gait impairment.
- Trial name
- MS-SPI (NCT02220933)
- Testing
- MD1003 100mg capsule
- Where
- 17 sites in France
- Volunteers
- 144 people
- Sponsor
- MedDay Pharmaceuticals SA
Healthy Volunteers, Multiple Sclerosis
Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients
In this first in human study the aim is to assess the safety, pharmacokinetics and pharmacodynamics of 2B3-201 in a randomized, first in human, double-blind, placebo- and active comparator- controlled 3-way crossover study in 18…
- Trial name
- NCT02048358
- Testing
- 2B3-201, Methylprednisolone hemisuccinate
- Where
- 2 sites in Netherlands
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- BBB-Therapeutics B.V.
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2)
- Trial name
- ENSURE-2 (NCT05201638)
- Testing
- IMU-838 tablets
- Where
- 101 sites in United States, Armenia and 12 more
- Volunteers
- 1,100 people
- Sponsor
- Immunic AG
Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Refractory Primary and Secondary Progressive Multiple Sclerosis
- Conditions
- Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, MS
- Trial name
- NCT06384976
- Testing
- KYV-101, Standard lymphodepletion regimen, Anti-CD20 mAB
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Kyverna Therapeutics
Multiple Sclerosis (MS)
An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis
In collaboration with the Mercy MS Achievement Center, Lumos Labs is proposing an open-label, 12-month pilot study of computerized cognitive training as part of the cognitive wellness program in order to evaluate (1) the user…
- Trial name
- NCT02612935
- Testing
- Lumosity
- Volunteers
- 88 people
- Sponsor
- Lumos Labs, Inc.
Relapsing-remitting Multiple Sclerosis (RRMS)
A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis
This is a randomized, controlled, multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of rocbrutinib (LP-168), an oral BTK inhibitor, in subjects with paramagnetic rim lesion (PRL)-positive…
- Trial name
- NCT07776743
- Testing
- Rocbrutinib, Dimethyl Fumarate
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.